☆ 4.8 Correction

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance (vol 9, eaan3788, 2017)

SCIENCE TRANSLATIONAL MEDICINE (2017)

Journal

SCIENCE TRANSLATIONAL MEDICINE

Volume 9, Issue 385, Pages -

Publisher

AMER ASSOC ADVANCEMENT SCIENCE

DOI: 10.1126/scitranslmed.aan3788

Keywords

-

Categories

Cell Biology Medicine, Research & Experimental

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Multidisciplinary Sciences

Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response

Anastasia Gangaev, Elisa A. Rozeman, Maartje W. Rohaan, Olga I. Isaeva, Daisy Philips, Sanne Patiwael, Joost H. van den Berg, Antoni Ribas, Dirk Schadendorf, Bastian Schilling, Ton N. Schumacher, Christian U. Blank, John B. A. G. Haanen, Pia Kvistborg

Summary: PD-1 blockade may primarily affect T cell composition in peripheral blood, while CTLA-4 blockade may result in the expansion of melanoma-reactive CD8 T cell response in peripheral blood.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Blockade of PD-1 and CTLA-4: A potent immunotherapeutic approach for hepatocellular carcinoma

Kai Hou, Xiaohui Xu, Xin Ge, Jiacen Jiang, Fan Ouyang

Summary: Immune checkpoints play a role in promoting tumor growth and inhibiting immune-mediated cancer cell apoptosis. Targeting immune checkpoints has been successful in treating various cancers, including hepatocellular carcinoma (HCC). However, some patients do not respond to this therapy due to acquired resistance and recurrence. Understanding the specific mechanisms of immune checkpoints in HCC development is crucial for improving the efficacy of anti-PD-1 and anti-CTLA-4 therapy.

BIOFACTORS (2023)

Add to Collection

Article Endocrinology & Metabolism

Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline

Shintaro Iwama, Tomoko Kobayashi, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Masahiko Ando, Xin Zhou, Ayana Yamagami, Takeshi Onoue, Yohei Kawaguchi, Takashi Miyata, Mariko Sugiyama, Hiroshi Takagi, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Masahiro Morise, Keiko Wakahara, Kenji Yokota, Masashi Kato, Naoki Nishio, Chie Tanaka, Kazushi Miyata, Atsushi Ogura, Takanori Ito, Tsunaki Sawada, Tomoya Shimokata, Kaoru Niimi, Fumiharu Ohka, Masatoshi Ishigami, Momokazu Gotoh, Naozumi Hashimoto, Ryuta Saito, Hitoshi Kiyoi, Hiroaki Kajiyama, Yuichi Ando, Hideharu Hibi, Michihiko Sone, Masashi Akiyama, Yasuhiro Kodera, Hiroshi Arima

Summary: The study revealed that the incidence of thyroid immune-related adverse events was high after PD-1/CTLA-4-Abs treatment even in patients negative for ATAs at baseline.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Add to Collection

Article Chemistry, Multidisciplinary

In vivo activated T cell targeting with PD-1/PD-L1 blockade for sequential treatment mediated cancer immunotherapy

Weijing Yang, Meng Zhang, Jinjie Zhang, Yanlong Liu, Jie Ning, Jing Yang, Zhenzhong Zhang, Lin Hou, Xiaoyuan Chen

Summary: Targeting pre-activated T cells with immune checkpoint blockade through sequential therapy enhances immune response and improves antitumor activity.

NANO TODAY (2022)

Add to Collection

Article Oncology

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

Claire F. Friedman, Christine Spencer, Christopher R. Cabanski, Katherine S. Panageas, Daniel K. Wells, Antoni Ribas, Hussein Tawbi, Katy Tsai, Michael Postow, Alexander Shoushtari, Paul Chapman, Joyson Karakunnel, Samantha Bucktrout, Pier Gherardini, Travis J. Hollmann, Richard O. Chen, Margaret Callahan, Theresa LaVallee, Ramy Ibrahim, Jedd Wolchok

Summary: This study compared the efficacy of different treatment methods in patients with advanced melanoma through a randomized trial. The results showed that both treatments could induce objective responses, with comparable disease control rates. The findings from biomarker analyses provided hypothesis-generating signals for further research.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Review Oncology

Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?

Pushpamali De Silva, Marco Aiello, Chunyan Gu-Trantien, Edoardo Migliori, Karen Willard-Gallo, Cinzia Solinas

Summary: Immunotherapy approaches targeting immune checkpoint molecules like CTLA-4 have revolutionized treatment of solid tumors and hematological malignancies by enhancing antitumor immune responses. However, the use of anti-CTLA-4 Abs may lead to autoimmune-like adverse events, though this higher incidence is associated with improved clinical benefit.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Review Oncology

Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies

Liming Liao, Huilin Xu, Yuhan Zhao, Xiaofeng Zheng

Summary: Immunotherapies based on immune checkpoint blockade have improved cancer therapy outcomes in the past decade. However, some patients show poor responsiveness to this therapy, and the underlying mechanism is not well understood. Recent studies have shown that targeting tumor metabolism in combination with immune checkpoint inhibitors provides new approaches to cancer therapy.

FRONTIERS OF MEDICINE (2023)

Add to Collection

Review Oncology

Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity

Allan Relecom, Maysaloun Merhi, Varghese Inchakalody, Shahab Uddin, Darawan Rinchai, Davide Bedognetti, Said Dermime

Summary: Immune checkpoint inhibitors have shown therapeutic benefits in solid cancers and some hematological malignancies, but predicting treatment response remains challenging. Studies on the dynamics of the immune system and tumor under immune checkpoint blockade have revealed mechanisms of action and adaptive resistance to these therapeutic agents.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Engineering, Environmental

Amplified cancer immunotherapy of PD-L1 blockade by sequential tumor microenvironment reshaping and DC maturation

Peng Hua, Di Jiang, Zhaopei Guo, Huayu Tian, Xuesi Chen, Meiwan Chen

Summary: A two-step sequential delivery strategy was developed to enhance the antitumor efficacy of anti-PD-L1 cancer therapy by remodeling the tumor microenvironment and increasing immune cell infiltration.

CHEMICAL ENGINEERING JOURNAL (2023)

Add to Collection

Article Oncology

Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors

Hemanth K. Potluri, Carolina A. Ferreira, Joseph Grudzinski, Christopher Massey, Eduardo Aluicio-Sarduy, Jonathan W. Engle, Ohyun Kwon, Ian R. Marsh, Bryan P. Bednarz, Reinier Hernandez, Jamey P. Weichert, Douglas G. McNeel

Summary: This study found that the combination of targeted radionuclide therapy (TRT) and PD-1 blockade therapy is ineffective in prostate cancer models due to the activating effect of anti-PD-1 on regulatory T cells (Tregs). The results emphasize the importance of understanding the effects of TRT and immunotherapy combinations on the tumor immune microenvironment before clinical investigation.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Review Immunology

Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action

Zena N. Willsmore, Ben G. T. Coumbe, Silvia Crescioli, Sara Reci, Ayushi Gupta, Robert J. Harris, Alicia Chenoweth, Jitesh Chauhan, Heather J. Bax, Alexa McCraw, Anthony Cheung, Gabriel Osborn, Ricarda M. Hoffmann, Mano Nakamura, Roman Laddach, Jenny L. C. Geh, Alastair MacKenzie-Ross, Ciaran Healy, Sophia Tsoka, James F. Spicer, Debra H. Josephs, Sophie Papa, Katie E. Lacy, Sophia N. Karagiannis

Summary: CTLA-4 and PD-1 are immune checkpoint molecules that are targets of antibody immunotherapies for malignant melanoma. Combination therapy with immune checkpoint inhibitors may have better outcomes compared to monotherapy in certain patient groups, but also presents challenges and increased rates of adverse events.

EUROPEAN JOURNAL OF IMMUNOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer

Jinrui Zhang, Ge Zhang, Wenjing Zhang, Lu Bai, Luning Wang, Tiantian Li, Li Yan, Yang Xu, Dan Chen, Wenting Gao, Chuanzhou Gao, Chaoqun Chen, Menglin Ren, Yuexia Jiao, Hongqiang Qin, Yu Sun, Lili Zhi, Yangfan Qi, Jinyao Zhao, Quentin Liu, Han Liu, Yang Wang

Summary: The RNA binding protein RBMS1 is prevalent in immune-cold triple-negative breast cancers (TNBC) and plays a role in regulating the stability of programmed death ligand 1 (PD-L1). Depletion of RBMS1 enhances cytotoxic T cell mediated anti-tumor immunity and combination with immune checkpoint blockade or CAR-T treatment further enhances anti-tumor T-cell immunity. Our findings provide a new immunotherapeutic strategy targeting the immunosuppressive RBMS1 in TNBC.

CELL DEATH AND DIFFERENTIATION (2022)

Add to Collection

Review Immunology

The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives

Jamal Majidpoor, Keywan Mortezaee

Summary: The interaction between PD-L1 and PD-1 is crucial for immune evasion in cancers, with PD-L1 positivity generally associated with higher responses to immune checkpoint inhibition (ICI) but also poor prognosis. Triple negative breast cancer (TNBC) is aggressive, but shows meaningful responses to ICI. Combining anti-PD-1/PD-L1 with immune modulatory drugs has shown significant clinical benefits.

CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade

Giovanni Randon, Yu Aoki, Romain Cohen, Leonardo Provenzano, Vincenzo Nasca, Samuel J. Klempner, Steven B. Maron, Riccardo Cerantola, Joseph Chao, Lorenzo Fornaro, Walter Ferrari Bravo, Filippo Ghelardi, Margherita Ambrosini, Paolo Manca, Massimiliano Salati, Akihito Kawazoe, Valerie Zhu, Darren Cowzer, Virginia Genovesi, Sara Lonardi, Kohei Shitara, Thierry Andre, Filippo Pietrantonio

Summary: This study found that immune checkpoint inhibitor-based therapy is superior to chemotherapy in patients with dMMR and/or MSI-high advanced gastric or gastroesophageal junction adenocarcinoma. However, more studies are needed to examine prognostic features within this patient population.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Add to Collection

Article Immunology

Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4

Katie Fisher, Timothy E. E. Schlub, Zoe Boyer, Thomas A. A. Rasmussen, Ajantha Rhodes, Rebecca Hoh, Frederick M. M. Hecht, Steven G. G. Deeks, Sharon R. R. Lewin, Sarah Palmer

Summary: By sorting cells with different cell surface markers, it was found that CD4(+) T cells expressing PD-1 have a higher integrity of HIV-1 genomes, while cells expressing CTLA-4 have more defective HIV-1 genomes. However, there is significant variation among individuals, indicating the need for additional cellular markers to accurately identify cells with latent and potentially replicative HIV-1.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Review Oncology

Sentinel Lymph Node Biopsy for Extremity and Truncal Soft Tissue Sarcomas: A Systematic Review of the Literature

Emily Z. Keung, Kate J. Krause, Jessica Maxwell, Carol D. Morris, Aimee M. Crago, Matthew T. Houdek, John Kane, Valerae Lewis, Dario Callegaro, Benjamin Miller, Alexander J. Lazar, Rebecca Gladdy, Chandrajit P. Raut, Nicola Fabbri, Waddah Al-Refaie, Mark Fairweather, Sandra L. Wong, Christina L. Roland

Summary: Regional lymph node metastasis (RLNM) is uncommon in patients with soft tissue sarcoma (STS), although certain STS subtypes are more prone to RLNM. The impact of node-positive disease on patient survival is still controversial. There is ongoing debate about the benefits of sentinel lymph node biopsy (SLNB) in STS patients. Further multicenter prospective studies are needed to determine the true incidence and potential benefits of SLNB in patients with clinically occult RLNM.

ANNALS OF SURGICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

Andrew W. Hahn, Ashley Menk, Dayana B. Rivadeneira, Ryan C. Augustin, Mingchu Xu, Jun Li, Xiaogang Wu, Aditya K. Mishra, Tuba N. Gide, Camelia Quek, Yan Zang, Christine N. Spencer, Alexander M. Menzies, Carrie R. Daniel, Courtney W. Hudgens, Theodore Nowicki, Lauren E. Haydu, M. A. Wadud Khan, Vancheswaran Gopalakrishnan, Elizabeth M. Burton, Jared Malke, Julie M. Simon, Chantale Bernatchez, Nagireddy Putluri, Scott E. Woodman, Y. N. Vashisht Gopal, Renato Guerrieri, Grant M. Fischer, Jian Wang, Khalida M. Wani, John F. Thompson, Jeffrey E. Lee, Patrick Hwu, Nadim Ajami, Jeffrey E. Gershenwald, Georgina Long, Richard A. Scolyer, Michael T. Tetzlaff, Alexander J. Lazar, Dirk Schadendorf, Jennifer A. Wargo, John M. Kirkwood, Ralph J. DeBerardinis, Han Liang, Andrew Futreal, Jianhua Zhang, James S. Wilmott, Weiyi Peng, Michael A. Davies, Greg M. Delgoffe, Yana G. Najjar, Jennifer L. McQuade

Summary: This study investigated the association between body mass index (BMI) and tumor or microbiome characteristics in patients with metastatic melanoma. The findings suggest that the host metabolic phenotype influences melanoma metabolism and may explain the improved outcomes observed in overweight/obese patients treated with immune checkpoint inhibitors and targeted therapies.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Oncology

Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness

Yize Li, Tung-Shing M. Lih, Saravana M. Dhanasekaran, Rahul Mannan, Lijun Chen, Marcin Cieslik, Yige Wu, Rita Jiu-Hsien Lu, David J. Clark, Iga Koodziejczak, Runyu Hong, Siqi Chen, Yanyan Zhao, Seema Chugh, Wagma Caravan, Nataly Naser Al Deen, Noshad Hosseini, Chelsea J. Newton, Karsten Krug, Yuanwei Xu, Kyung-Cho Cho, Yingwei Hu, Yuping Zhang, Chandan Kumar-Sinha, Weiping Ma, Anna Calinawan, Matthew A. Wyczalkowski, Michael C. Wendl, Yuefan Wang, Shenghao Guo, Cissy Zhang, Anne Le, Aniket Dagar, Alex Hopkins, Hanbyul Cho, Felipe da Veiga Leprevost, Xiaojun Jing, Guo Ci Teo, Wenke Liu, Melissa A. Reimers, Russell Pachynski, Alexander J. Lazar, Arul M. Chinnaiyan, Brian A. Van Tine, Bing Zhang, Karin D. Rodland, Gad Getz, D. R. Mani, Pei Wang, Feng Chen, Galen Hostetter, Mathangi Thiagarajan, W. Marston Linehan, David Fenyo, Scott D. Jewell, Gilbert S. Omenn, Rohit Mehra, Maciej Wiznerowicz, Ana I. Robles, Mehdi Mesri, Tara Hiltke, Eunkyung An, Henry Rodriguez, Daniel W. Chan, Christopher J. Ricketts, Alexey I. Nesvizhskii, Hui Zhang, Li Ding

Summary: By integrating histopathologic, proteogenomic, and metabolomic analyses, this study reveals the inter- and intratumoral heterogeneity of clear cell renal cell carcinomas (ccRCCs). It identifies high-risk disease subsets based on tumor grade, BAP1 mutation, genome instability, hypermethylation, and protein glycosylation signature. RNA sequencing provides insights into gene signatures and potential targeted therapies, while in vitro cell line studies validate the efficacy of inhibiting identified phosphoproteome targets.

CANCER CELL (2023)

Add to Collection

Article Oncology

Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time

Tuyen Duong Thanh Nguyen, Yan Wang, Tuyen N. Bui, Rossana Lazcano, Davis R. Ingram, Min Yi, Varshini Vakulabharanam, Linjie Luo, Marc A. Pina, Cansu Karakas, Mi Li, Nicole M. Kettner, Neeta Somaiah, Peter J. Hougton, Osama Mawlawi, Alexander J. Lazar, Kelly K. Hunt, Khandan Keyomarsi

Summary: Treatment strategies with CDK4/6 inhibitors followed by DNA-damaging agents showed synergistic killing of Rb-positive sarcomas and can be noninvasively monitored using functional imaging and serum biomarkers. This approach provides a potential avenue for novel targeted therapies in sarcomas with intact Rb signaling.

CANCER RESEARCH (2023)

Add to Collection

Article Oncology

Changes in outcomes and factors associated with survival in melanoma patients with brain metastases

Merve Hasanov, Denai R. Milton, Alicia Bea Davies, Elizabeth Sirmans, Chantal Saberian, Eliza L. Posada, Sylvia Opusunju, Jeffrey E. Gershenwald, Carlos A. Torres-Cabala, Elizabeth M. Burton, Rivka R. Colen, Jason T. Huse, Isabella C. Glitza Oliva, Caroline Chung, Mary Frances McAleer, Susan L. McGovern, Debra N. Yeboa, Betty Y. S. Kim, Sujit S. Prabhu, Ian E. McCutcheon, Jeffrey S. Weinberg, Frederick F. Lang, Hussein A. Tawbi, Jing Li, Lauren E. Haydu, Michael A. Davies, Sherise D. Ferguson

Summary: This study evaluates changes in clinical features and overall survival (OS) for patients with melanoma brain metastasis (MBM). The treatment options for MBM have significantly changed in the last decade, leading to improved OS. Factors associated with survival in MBM patients include patient age, primary tumor Breslow thickness, prior immunotherapy, leptomeningeal disease, symptomatic MBMs, and whole brain radiation therapy in the current era.

NEURO-ONCOLOGY (2023)

Add to Collection

Editorial Material Oncology

Mitotic rate in primary cutaneous melanoma: Cell division matters

Jeffrey E. Gershenwald

Summary: The prognostic significance of primary cutaneous melanoma tumor mitotic rate (TMR) has been of interest in the clinical field worldwide for many years. Is there a way to utilize the findings from Patuzzo et al. and other studies to enhance the classification and staging of melanoma, as well as develop clinical tools that incorporate TMR for improved risk and prognostic assessment?

CANCER (2023)

Add to Collection

Article Oncology

Melanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management

Elliot A. Asare, Sarah B. Fisher, Yi-Ju Chiang, Lauren E. Haydu, Sameer H. Patel, Emily Z. Keung, Anthony Lucci, Jennifer Wargo, Jeffrey E. Gershenwald, Merrick I. Ross, Jeffrey. E. Lee

Summary: Adrenectomy in patients with metastatic melanoma is associated with prolonged survival, especially when done selectively. Factors such as immune checkpoint blockade therapy and selection for surgery were found to be strongly associated with improved survival after adrenal metastasis diagnosis.

JOURNAL OF SURGICAL ONCOLOGY (2023)

Add to Collection

Correction Multidisciplinary Sciences

Neoadjuvant relatlimab and nivolumab in resectable melanoma (vol 611, pg 155, 2022)

Rodabe N. Amaria, Michael Postow, Elizabeth M. Burton, Michael T. Tetzlaff, Merrick I. Ross, Carlos Torres-Cabala, Isabella C. Glitza, Fei Duan, Denai R. Milton, Klaus Busam, Lauren Simpson, Jennifer L. McQuade, Michael K. Wong, Jeffrey E. Gershenwald, Jeffrey E. Lee, Ryan P. Goepfert, Emily Z. Keung, Sarah B. Fisher, Allison Betof-Warner, Alexander N. Shoushtari, Margaret Callahan, Daniel Coit, Edmund K. Bartlett, Danielle Bello, Parisa Momtaz, Courtney Nicholas, Aidi Gu, Xuejun Zhang, Brinda Rao Korivi, Madhavi Patnana, Sapna P. Patel, Adi Diab, Anthony Lucci, Victor G. Prieto, Michael A. Davies, James P. Allison, Padmanee Sharma, Jennifer A. Wargo, Charlotte Ariyan, Hussein A. Tawbi

NATURE (2023)

Add to Collection

Article Oncology

Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma

Gabriele Romano, Francesca Paradiso, Peng Li, Pooja Shukla, Lindsay N. Barger, Olivia El Naggar, John P. Miller, Roger J. Liang, Timothy L. Helms, Alexander J. Lazar, Jennifer A. Wargo, Francesca Taraballi, James C. Costello, Lawrence N. Kwong

Summary: Patients with BRAF-mutant melanoma respond well to combined BRAF and MEK inhibition, but relapse is common within 2 years. Minimal residual disease (MRD), which consists of drug-tolerant tumor cells in a dormant state, is a major cause of drug resistance. By studying a mouse model, researchers found that sustaining chemokine signaling can impair MRD maintenance by increasing the recruitment of effector T cells.

CANCER IMMUNOLOGY RESEARCH (2023)

Add to Collection

Review Oncology

Targeting the Molecular and Immunologic Features of Leiomyosarcoma

Brandon M. Cope, Raymond S. Traweek, Rossana Lazcano, Emily Z. Keung, Alexander J. Lazar, Christina L. Roland, Elise F. Nassif

Summary: Immunotherapy has greatly improved cancer care, but leiomyosarcoma is not responsive to early immune-based therapies. This review discusses the results of immunotherapy trials in leiomyosarcoma and highlights the differences between soft-tissue and uterine leiomyosarcomas. It also explores the molecular subgroups of leiomyosarcomas and their impact on response to immune checkpoint blockade, proposing future directions for improving immunotherapy in leiomyosarcoma patients. Leiomyosarcoma is a rare and aggressive tumor with low tumor mutational burden, frequent alterations in certain genes, and a highly infiltrated immune microenvironment. This review provides insights for the development of biomarker-based immune therapies.

CANCERS (2023)

Add to Collection

Article Dermatology

Telomerase reverse transcriptase immunohistochemical expression is sensitive but not specific for TERT gene amplification in acral melanoma

Woo Cheal Cho, Wen Li, Jun Gu, Wei-Lien Wang, Jing Ning, Steven Sfamenos, Pavandeep Gill, Priyadharsini Nagarajan, Jonathan L. Curry, Alexander J. Lazar, Victor G. Prieto, Carlos A. Torres-Cabala, Phyu P. Aung

Summary: The clinical utility of TERT IHC to predict TGA status in AMs appears to be limited given its low specificity and positive predictive value.

JOURNAL OF CUTANEOUS PATHOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

The epigenetic impact and therapeutic opportunity of AR-directed therapy for desmoplastic small round cell tumor

Danh D. Truong, Salah-Eddine Lamhamedi-Cherradi, Mayinuer Maitituoheti, Hannah C. Beird, Chia-Chin Wu, Sandhya Krishnan, Davis Ingram, P. Andrew Futreal, Mark Titus, Alexander Lazar, Kunal Rai, A. Robert MacLeod, Najat C. Daw, Andrea Hayes, Joseph Ludwig

CANCER RESEARCH (2023)

Add to Collection

Meeting Abstract Medicine, Research & Experimental

TRPS1 Expression is a Marker for Malignancy in Peripheral Nerve Sheath Tumors

Rossana Lazcano, Davis Ingram, Alexander Lazar, Wei-Lien (Billy) Wang, Jeffrey Cloutier

LABORATORY INVESTIGATION (2023)

Add to Collection

Meeting Abstract Medicine, Research & Experimental

Improved Pathological Response in Undifferentiated Pleomorphic Sarcoma (UPS) Treated by Concurrent Immunotherapy and Radiation Therapy (RT) Compared with Radiation Therapy Alone

Rossana Lazcano, Raymond Traweek, Davis Ingram, Khalida Wani, B. Ashleigh Guadagnolo, Ahsan Farooqi, Christina Roland, Emily Keung, Andrew Bishop, Wei-Lien (Billy) Wang, Elise Nassif, Alexander Lazar

LABORATORY INVESTIGATION (2023)

Add to Collection

Meeting Abstract Medicine, Research & Experimental

GPNMB Can Be a Useful Ancillary Tool to Identify Perivascular Epithelioid Cell Tumor (PEComa)

Sintawat Wangsiricharoen, Davis Ingram, Alexander Lazar, Wei-Lien (Billy) Wang

LABORATORY INVESTIGATION (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.